{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:09:25Z","timestamp":1774451365248,"version":"3.50.1"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors cause rare but potentially fatal neuromuscular complications, leading to a concern to use these agents in cancer patients with pre-existing autoimmune or inflammatory neuromuscular diseases. We report two such patients with paraneoplastic dermatomyositis and \u201cseronegative\u201d paraneoplastic demyelinating neuropathy, respectively, who have been successfully treated with immune checkpoint inhibitor monotherapy as well as maintenance intravenous immunoglobulin. While controlling the paraneoplastic or autoimmune neuromuscular diseases, the use of intravenous immunoglobulin did not compromise the anti-cancer effect of immune checkpoint inhibitor.<\/jats:p>","DOI":"10.3389\/fonc.2023.1199195","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T06:57:18Z","timestamp":1688367438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Ge","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard Benjamin","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanual","family":"Maverakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo A.","family":"Maselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Paul","family":"Richman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-326369","article-title":"Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours","volume":"93","author":"Chompoopong","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.det.2018.07.009","article-title":"Skin cancer and immunosuppression","volume":"37","author":"Collins","year":"2019","journal-title":"Dermatol Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153098","article-title":"Thyroid cancer and thyroid autoimmune disease: a review of molecular aspects and clinical outcomes","volume":"216","author":"Dias Lopes","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12283","article-title":"The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China","volume":"42","author":"Zhou","year":"2022","journal-title":"Cancer Commun (Lond)."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001460","article-title":"Rethinking immune checkpoint blockade: 'Beyond the T cell'","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e32834a87b7","article-title":"Paraneoplastic neuropathy: wide-ranging clinicopathological manifestations","volume":"24","author":"Koike","year":"2011","journal-title":"Curr Opin Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-005-0942-1","article-title":"Paraneoplastic syndromes in patients with primary malignancies of the head and neck: four cases and a review of the literature","volume":"263","author":"Baijens","year":"2006","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S369908","article-title":"Cancer diagnosis and prognosis after Guillain-Barr\u00e9 syndrome: a population-based cohort study","volume":"14","author":"Girma","year":"2022","journal-title":"Clin Epidemiol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"De Vooght","year":"2020","journal-title":"Rheumatol (Oxford)."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1199195\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T06:57:20Z","timestamp":1688367440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1199195\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":16,"alternative-id":["10.3389\/fonc.2023.1199195"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1199195","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"article-number":"1199195"}}